Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was October 18, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares. The exempt principal trader purchased 180,000 shares at a highest price per unit of 0.0127 and sold 1,020,000 shares at a highest price per unit of 0.014. The lowest price per unit paid/received for both purchases and sales was 0.0127 and 0.0125, respectively.
The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.
The contact name provided for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969. The form concludes by stating that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.